"Breakthrough treatment is adverse to long-term business," claimed by analysts at Goldman Sachs

byCarlos Reusser Monsalvez

Securities companyGoldman SachsAccording to the report by "Report on innovative treatment that will cure illness in one shot, for long-term benefit," in response to the question "Are patients under treatment becoming a sustainable business model?" It has been pointed out that there is an adverse effect "and controversial.

Goldman asks: 'Is curing patients a sustainable business model?'
https://www.cnbc.com/2018/04/11/goldman-asks-is-curing-patients-a-sustainable-business-model.html

Saruvin Richter says, an analyst at Goldman Sachs, in the April 10, dated report, "The Genome Revolution", therapy with "gene therapy and genetic engineering can cure" any disease even in one shot there is a possibility to produce a breakthrough therapy ", there is a charming aspects. However, considering the points have been obtained regular income by existing therapies, innovative therapies, totally It can be caught in a different view. "

byUniversity of Michigan Scool for Environment and Sustainability's photostream

One example in the report is "Gilead SciencesIt is a hepatitis C treatment drug. The treatment of hepatitis C marketed by Gilead Sciences is highly effective, it is said that the cure rate exceeds 90%, and sales of hepatitis C therapeutic drugs in 2015 will be $ 12.5 billion (about 1.3 trillion yen ) It is said that it reached. However, as many people were treated, as the number of people infected with hepatitis C decreased, the sales declined. Analysts at Goldman Sachs forecast that sales of Gilead Sciences' hepatitis C drugs in 2018 will be less than $ 4 billion (about 430 billion yen).

bydon

Richter said, "By developing innovative treatments for infectious diseases and treating existing patients, the number of carriers that can infect new patients with viruses also decreases, Gilliad Sciences "We have exhausted patients that can be treated little by little." If you are a hereditary disease such as cancer that is not an infectious disease or general illness or haemophilia, business continuity The possibility risk is reduced ".

Treat leukemia girl by editing genomeGene therapy, including genome editing, has the potential to be a breakthrough treatment for diseases that could not be treated in the past. Mr. Richter's remark that "a business is established only when there is a patient to be treated" also raises voices of criticism that it is "cruel and non-moral".

Just in case you had any question exactly how cold and immoral the big banks are, here is a reminder.

Another reminder is that if we elect a#BrandNewCongressWe can use our money to invest in things like gene therapy to actually cure what ails us!https://t.co/HnxkXY1off

- Marc Whitmire (@ whitmire 2018)April 12, 2018